Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

U.S. Invests in Amgen, Sanofi Countermeasures for Radiological Incidents

by Global Biodefense Staff
October 11, 2016
Radiation Medical Countermeasures

Radiation Medical CountermeasuresThe U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) is purchasing two medical products to treat injuries to bone marrow in victims of radiological or nuclear accidents or acts of terrorism.

The two products, called colony stimulating factors, stimulate bone marrow to produce blood cells including neutrophils that reduce the body’s risk of developing an infection and decrease risk of death from acute radiation syndrome.

Infections often occur after exposure to high doses of radiation. These types of products are used commonly to reduce the risk of infection in patients with cancer.

ASPR’s Biomedical Advanced Research and Development Authority (BARDA) is purchasing the first of these two leukocyte growth factor products, called Neulasta, from Amgen USA, Inc. of Thousand Oaks, California, under an approximately $37.7 million agreement. BARDA will purchase the second product, called Leukine, from Sanofi-Aventis U.S., LLC of Bridgewater, New Jersey, under a $37.6 million agreement. Sanofi-Aventis is a subsidiary of Sanofi.

Neulasta is approved by the U.S. Food and Drug Administration (FDA) to treat adults and children exposed to high levels of radiation that damage bone marrow. BARDA continues to work with Sanofi-Aventis to support the studies needed to request FDA approval of Leukine.

BARDA will purchase both products using funding and authority provided through the Project BioShield Act of 2004. Under the Project BioShield Act, the U.S. government supports the advanced development and procurement of new medical countermeasures – drugs, vaccines, diagnostics, and medical supplies – to protect health against chemical, biological, radiological and nuclear threats.

The products add to the available treatment options in the Strategic National Stockpile for acute radiation syndrome. Previously, BARDA sponsored advanced development and purchased another leukocyte growth factor product called Neupogen, which is now also FDA-approved for use in treating adults and children exposed to levels of radiation that damage the bone marrow.

The purchase of Neulasta and Leukine increases the number of colony stimulating factor doses available for use in an emergency response. It also increases operational capability since treatments with Neulasta are given once weekly, whereas treatment with Neupogen are given daily.

Tags: ASPRAwardsBARDAHHSRadiationStrategic National Stockpile

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC